Avantogen’s Hawaii Biotech Inc. receives clinical trial support from Walter Reed Army Institute of Research

03-Sep-2008 - USA

Avantogen Ltd announced additional support for the Dengue vaccine program developed by Hawaii Biotech Inc, in which Avantogen holds a significant investment stake. The Dengue clinical trial will be conducted as part of a broader trial at the clinical trials centre of the US Walter Reed Army Institute of Research (WRAIR). This institution has a well recognised competency in emerging infectious disease and considerable experience with dengue fever, according to the company.

Avantogen believes that a partnership with a reputable organisation such as WRAIR gives further validation of the Hawaii Biotech Inc vaccine technology platform and the actual dengue vaccine candidate that has been developed. Furthermore, Avantogen (and Hawaii Biotech Inc) have also gained a potential partner to accelerate the program. Next steps could be the dosage of first subjects with the proprietary, recombinant-DNA-based vaccine candidate being developed by Hawaii Biotech Inc.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances